Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro-Reference-Cited by-同舟云学术

Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro

Published:2006-09-29 Issue:6 Volume:56 Page:849-861
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Chen Jinfei,Schmitt Anita,Chen Baoan,Rojewski Markus,Ringhoffer Mark,von Harsdorf Stephanie,Greiner Jochen,Guillaume Philippe,Döhner Hartmut,Bunjes Donald,Schmitt Michael

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-006-0232-9.pdf

Reference48 articles.

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037

2. Savage DG, Antman KH (2002) Imatinib mesylate—a new oral targeted therapy. N Engl J Med 346:683–693

3. Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE (2002) Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood 100:1088–1091

4. Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Bekassy AN, Gadner H, Sufliarska S, Stary J, Gschaidmeier H, Guilhot F, Suttorp M (2006) Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 20:187–192

5. Ramanarayanan J, Dunford LM, Baer MR, Sait SN, Lawrence W, McCarthy PL (2006) Chronic myeloid leukemia after treatment of lymphoid malignancies:Response to imatinib mesylate and favorable outcomes in three patients. Leuk Res 30:701–705

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing;Cytotherapy;2022-09

2. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape;Leukemia;2021-04-08

3. Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report;Clinical Rheumatology;2018-03-21

4. Increase of T and B cells and altered BACH2 expression patterns in bone marrow trephines of imatinib-treated patients with chronic myelogenous leukaemia;Oncology Letters;2016-08-05

5. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation;International Journal of Cancer;2015-11-27